TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21382484
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine with a 12-month interval between doses (MMRV-12M)
Study: 21382484
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine with a 4-week interval between doses (MMR)
Study: 16722837
Drug: Antidiabetic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic medication
Study: 12057040
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m2 over 30 minutes on days 1 and 8 every 21 days plus trastuzumab 4 mg/kg over 90 minutes, followed by 2 mg/kg weekly.
Study: 12057040
Drug: Gemcitabine/trastuzumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/trastuzumab treatment
Study: 10460066
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg l-menthol capsule
Study: 10460066
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg menthol in mint candy or mint tea
Study: 1971650
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g CAZ administered 140 min prior to puncture (group I)
Study: 1971650
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 2 g CAZ one day before and 2 g 2 h prior to puncture (group II)
Study: 1971650
Drug: CAZ concentrations
Normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAZ concentrations at 4 h after infusion
Study: 1971650
Drug: CAZ concentrations
Normalized name: CAZ
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAZ concentrations at 6 h after infusion
Study: 383133
Drug: BCG in
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG in weekly scarifications for 3 years
Study: 30005584
Drug: DBT skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT skills training adjunctive to individual treatment as usual (TAU)
Study: 30005584
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment as usual (TAU) only
Study: 27437887
Drug: Ad5.hAC6 (D4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5.hAC6 (D4 + 5 doses)
Study: 24640801
Drug: Rocuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.06 mg/kg 1 minute before succinylcholine
Study: 24640801
Drug: Rocuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.06 mg/kg 5 minutes before succinylcholine
Study: 24640801
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 5 ml as placebo 1 minute before succinylcholine
Study: 22732780
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fosfomycin trometamol
Study: 16284985
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of standard-dose consolidation therapy without maintenance (Arm A)
Study: 16284985
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of standard-dose consolidation with six courses of maintenance therapy (Arm B)
Study: 10462658
Drug: Endoscopic variceal
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic variceal band ligation plus low-dose endoscopic variceal sclerotherapy
Study: 1967516
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg vecuronium
Study: 347467
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prodipin infusion (group 1)
Study: 347467
Drug: Continued therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued therapy without prodipin (group 2)
Study: 347467
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prodipin infusion (group 3)
Study: 31676120
Drug: Controlled-Flux Electrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-Flux Electrolyzed Acidic Solution (CFEAS)
Study: 28417897
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (800 mg magnesium oxide daily)
Study: 26552185
Drug: Psoraleae Fructus
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psoraleae Fructus (40 g x kg(‐1))
Study: 26552185
Drug: Psoraleae Fructus
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psoraleae Fructus and Glycyrrhizae Radix et Rhizoma (40 + 20 g x kg(‐1))
Study: 21485075
Drug: Physical comprehensive
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical comprehensive therapy
Study: 17547588
Drug: Sibutramine (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (5-15 mg/day)
Study: 15503549
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel treatment for severe periodontitis
Study: 9468466
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment with adjusted doses of methotrexate, teniposide, and cytarabine based on drug clearance rates.
Study: 9468466
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with fixed doses of methotrexate, teniposide, and cytarabine based on body-surface area.
Study: 9468466
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment for B-lineage leukemia patients.
Study: 9468466
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for T-lineage leukemia patients.
Study: 9468466
Drug: Methotrexate in
Normalized name: methotrexate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate in individualized treatment.
Study: 8542807
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) 2.4 g daily by mouth
Study: 2193998
Drug: standard broad
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard broad spectrum antibiotic therapy
Study: 31697336
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing (4g/24h after a loading dose of 1g)
Study: 31697336
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing (1g every 6h)
Study: 19595295
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE)
Study: 19156894
Drug: Chemotherapy (phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (phase 2)
Study: 19156894
Drug: Chemotherapy, autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, autologous SCT, and allogeneic SCT (phase 2)
Study: 17484870
Drug: Erythromycin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (12.5 mg/kg/dose every 6 hours for 14 days)
Study: 9565436
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplements (100,000 IU for children ≤1 year and 200,000 IU for children >1 year on admission, followed by 50,000 IU and 100,000 IU respectively the next day)
Study: 3279698
Drug: BCG RIVM
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG RIVM (1 x 10(9) bacilli in 50 mL saline) administered once a week for six consecutive weeks
Study: 3279698
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (30 mg in 50 mL saline) administered once a week for one month and thereafter once a month for a total of six months
Study: 20876922
Drug: Long-term TENS
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term TENS therapy via L-S orthoses (3 times a day for 20 minutes)
Study: 20876922
Drug: Conventional TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TENS therapy (once a day for 20 minutes)
Study: 17160228
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node detection using patent blue alone or in association with radiotracer based on technetium 99m colloid solution.
Study: 14981970
Drug: sME treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: sME treatment (therapy group)
Study: 14981970
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no complementary treatment)
Study: 8456467
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug therapy (low-dose cyclosporine, azathioprine, methylprednisolone)
Study: 3079888
Drug: Parlodel, 2.5
Normalized name: Parlodel, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel, 2.5 mg daily for 1-3 months
Study: 26966353
Drug: Optimized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulation of CTZ-loaded polymethacrylate microspheres (10 mg CTZ)
Study: 26966353
Drug: Commercial product
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial product of CTZ (marketed CTZ tablets)
Study: 25011515
Drug: Preoperative high-dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative high-dose-rate intracavitary brachytherapy (2x8Gy)
Study: 25011515
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (no preoperative treatment)
Study: 16688997
Drug: Ginaton (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton (0.5 mg/kg) added to St. Thomas' cardioplegic perfusion
Study: 15151330
Drug: Colgate Simply‐White
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colgate Simply‐White Whitening Gel (5.9% hydrogen peroxide)
Study: 2412032
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg b.i.d. given orally for 4 days
Study: 10506679
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg daily
Study: 7611241
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg) on low salt diet (50 mmol Na/d)
Study: 7611241
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg) on high salt diet (200 mmol Na/d)
Study: 7611241
Drug: Irbesartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (50 mg) on moderate salt diet (100 mmol Na/d)
Study: 6469428
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 50 mg atenolol and 12.5 mg chlorthalidone (Tenoretic Mite)
Study: 31262768
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of TBPM-PI-HBr at 100 mg to 900 mg
Study: 31262768
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of TBPM-PI-HBr at 300 mg or 600 mg every 8 hours
Study: 31262768
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of TBPM-PI-HBr at 600 mg q8h
Study: 16062094
Drug: Quetiapine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (400 mg/day)
Study: 16234046
Drug: Atropine (.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (.02 mg/kg)
Study: 16234046
Drug: Erythromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1 or 3 mg/kg)
Study: 10425980
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine (30 mg)
Study: 2075382
Drug: Mebendazole-citrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole-citrate (500 mg) given daily for 14 days
Study: 2075382
Drug: Mebendazole-citrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole-citrate (500 mg) given twice daily for 14 days
Study: 2075382
Drug: Levamisole 150
Normalized name: levamisole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 150 mg (two priming doses)
Study: 6753559
Drug: sulfinpyrazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfinpyrazone (200 mg 4 times daily)
Study: 31534549
Drug: COX-2 specific
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 specific inhibitor Rofecoxib
Study: 29105115
Drug: Taurine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (6 g/day)
Study: 27348000
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 4 mg∙kg(‐1)
Study: 14716219
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg)
Study: 14716219
Drug: Verapamil (SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (SR 160 mg)
Study: 7990325
Drug: Complex pathogenetic
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex pathogenetic approach including wide operative access, one-stage cleansing with antiseptics and detoxification solutions, ultrasonic cavitation, creation of laparostomy, local infiltration with 0.01% thymalin solution, correction of hemostasis disorders, increase of general reactivity
Study: 23553790
Drug: Tanezumab 10
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 10 mg
Study: 16368878
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) combined with effective antiretroviral therapy (ART)
Study: 9279183
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6 or 0, 1, 2, 12, with or without immunoglobulin at birth
Study: 29477098
Drug: Bright white-light
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white-light treatment (BLT, 10 000 lx, irradiance 31.7 W/m2)
Study: 25253184
Drug: Pidotimod 400
Normalized name: pidotimod 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 400 mg/die
Study: 21790446
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment (50 mg for 5 days, then 75 mg for 7 days)
Study: 22296865
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment
Study: 18686772
Drug: Oral‐B Triumph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Triumph
Study: 15929954
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg once daily for 3 days
Study: 15929954
Drug: Azithromycin once
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin once daily for 5 days
Study: 15929954
Drug: Amoxicillin 875
Normalized name: amoxicillin 875 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days
Study: 15929954
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg for 3 days
Study: 15929954
Drug: Amoxicillin/clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate for 10 days
Study: 12642969
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotiam intravenously 30 min to 4 h before tonsillectomy
Study: 12642969
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cefuroxime axetil orally 1 to 6 h before tonsillectomy
Study: 1398498
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (all doses)
Study: 28109492
Drug: Speech pathology
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech pathology treatment on-site without audiovisual materials
Study: 25588704
Drug: CYP3A4 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4 genotype effect on Tac Co/dose
Study: 21332383
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg NOMAC/1.5 mg E(2) (n = 9)
Study: 21332383
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg NOMAC/1.5 mg E(2) (n = 10)
Study: 21332383
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg NOMAC/1.5 mg E(2) (n = 10)
Study: 21332383
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg NOMAC alone (n = 9)
Study: 15710810
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL conjunctival irrigation of 5% povidone-iodine
Study: 9860040
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium inhalation solution mixed into a water‐based emollient cream at a final concentration of 0.21% for 1 month (phase I)
Study: 9860040
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium inhalation solution mixed into a water‐based emollient cream at a final concentration of 0.21% after crossover
Study: 7595909
Drug: Renal excretion
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal excretion of dopa and dopamine
Study: 2404430
Drug: PCEA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA using 0.125% bupivacaine with fentanyl 1 micrograms/ml (BF)
Study: 2404430
Drug: PCEA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA using 0.125% bupivacaine with fentanyl 1 micrograms/ml and 1:400,000 epinephrine (BFE)
Study: 2404430
Drug: Physician-controlled continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-controlled continuous epidural infusion using 0.125% bupivacaine (CEI)
Study: 320807
Drug: HC 20-511
Normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HC 20-511 (2.0 mg single dose or two times 1.0 mg for 3 days)
Study: 30950680
Drug: Gatifloxacin 0.5%
Normalized name: GATIFLOXACIN 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 0.5% ophthalmic solution
Study: 26136133
Drug: Multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple injections (control)
Study: 18005442
Drug: Quinimax (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinimax (20 mg/ml) administered via intra-rectal route
Study: 15159226
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g fish oil (1.5 g EPA and 1.0 g DHA) daily for 12 weeks
Study: 15159226
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g olive oil (control) daily for 12 weeks
Study: 11194073
Drug: Prehospital 12-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital 12-lead electrocardiograms and initiation of thrombolytic therapy
Study: 31231969
Drug: Therapists' judgment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists' judgment of treatment response and remission using parent-reported SCARED after acute treatment
Study: 31231969
Drug: Therapists' judgment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapists' judgment of treatment response and remission using parent-reported SCARED after follow-up care
Study: 23479422
Drug: Lapatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib at 750 mg/day with paclitaxel and trastuzumab (THL)
Study: 23479422
Drug: Lapatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib at 750 mg/day
Study: 14769225
Drug: 0.3% ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ofloxacin topical drops
Study: 14769225
Drug: 0.3% ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ciprofloxacin topical drops
Study: 14769225
Drug: 0.3% tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% tobramycin topical drops
Study: 1451220
Drug: Hyaluronidase (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (7.5 IU.ml‐1) with etidocaine
Study: 1451220
Drug: Hyaluronidase (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (15 IU.ml‐1) with etidocaine
Study: 6379307
Drug: Insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1 U/kg/hr) with 33% glucose infusion (0.5 gm/kg/h) and potassium (0.25 mEq/kg/hr)
Study: 31982605
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg, twice a day
Study: 30297369
Drug: SUBA itraconazole
Normalized name: ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUBA itraconazole (2 65-mg capsules twice a day) under fasting conditions
Study: 30297369
Drug: SUBA itraconazole
Normalized name: ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SUBA itraconazole (2 65-mg capsules/day) with omeprazole (1 40-mg capsule/day)
Study: 27368067
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy (RT), 30 Gy in five fractions to the operative bed with 2- to 3-cm margins.
Study: 22393088
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy (RT)
Study: 22640563
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation (200 μg twice daily)